Yuk Yin Ng

Yardımcı Doçent Doktor

Mühendislik ve Doğa Bilimleri Fakültesi / Genetik ve Biyomühendislik Bölümü

  • #
  • Academic Background

    • 2003, PhD., Immunology and Hematology, University Medical Center Utrecht
    • 1996, MS., Medical Biology, Vrije University Amsterdam
    • 1993, BS., Biochemistry, University of Applied Sciences of Rotterdam

     

    Academic Appointments

    • 2013-present, Assistant Professor, Istanbul Bilgi University, Dept. of Genetics and Bioengineering
    • 2009-2010, Postdoctoral Fellow, Leiden University Medical Center, Immunohematology and Bloodtransfusion, Leiden / Netherlands
    • 2005-2009, Postdoctoral Fellow, Erasmus Medical Center, Department of Immunology

     

    Research Interests

    • Immunology / Immunogenetics
    • Stem Cell Biology
    • Gene Therapy
    • Molecular and Cell Biology

     

    Teaching

    • BIOE 102 General Biology
    • BIOE 222 Cell Biology, Spring
    • BIOE 321 Molecular Biology
    • BIOE 325 Cell and Tissue Culture
    • BIOE 428 Immunology
    • BIOE 424 Cancer Biology

     

    Projects

    • X’e Bağlı Agammaglobulinemi (XlA) Fare Modelinde B- Hücre Hasarının Düzeltilmesi . TUBITAK 1001, (principal investigator)
    • Yaygın Değişken İmmün Yetersizlik (CVID) Hastalarında CD19, ICOS, TACI, BAFF-R Gen Mutasyonlarının Araştırılması. Istanbul University, Research Foundation (Co-Advisor for the MSc Thesis)
    • Primer İmmün Yetersizliklerde Genetik Alt Yapının Yeni Nesil Dizileme Yöntemi ile Belirlenmesi. Istanbul University, Research Foundation, (Co-advisor for the PhD thesis) 2015-2017
    • Ağır Kombine İmmün Yetersizliklerin Yeni Nesil Teknolojiler İle Tüm Genom Analizleri Çok Disiplinli Öncelikli Alan Araştırma Projesi. Istanbul University, Research Foundation (BAP-ONAP), (collaborator) 2016-
    • Primer Antikor Yetersizliklerindeki Genetik Varyasyonların Yeni Nesil Dizileme Yöntemi ile Araştırılması . Istanbul University, Research Foundation (BAP-YOP), (collaborator) 2016-,
    • Yaygın Değişken İmmün Yetersizlikte Görülen Genetik Mutasyonların Yeni Nesil Dizileme Sistemi ile Taranması ve Bu Mutasyonların Hastalığın Kliniği ve Prognozu ile İlişkisi. Istanbul University, Research Foundation (BAP), (collaborator) 2016-
    • Farmakolojik Açıdan Önemli Olabilecek Yeni Heterohalkalı Bileıiklerin Sentezlenmesi. Yildiz Technical University, Research Foundation(collaborator) 2016-

     

    Selected Publications

    1. X-linked agammaglobulinemia in two siblings who have novel mutation in BTK gene presented with polyarticular juvenile idiopathic arthritis. Patiroglu T, Akar HH, Gunduz Z, Sisko S, Ng YY. Scan J Rheumatol.. 2015 44(2):168-70
    2. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Pike-Overzet K, Rodijk M, Ng YY, Baert MR, Lagresle-Peyrou C, Schambach A, Zhang F, Hoeben RC, Hacein-Bey-Abina S, Lankester AC, Bredius RG, Driessen GJ, Thrasher AJ, Baum C, Cavazzana-Calvo M, van Dongen JJ, Staal FJ. Leukemia. 2011 Sep;25(9):1471-83
    3. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Yuk Yin Ng, Miranda R.M. Baert, Karin Pike-Overzet, Mark Rodijk, Axel Schambach, Christopher Baum, Rudi W. Hendriks Jacques J.M. van Dongen and Frank J.T. Staal. Leukemia, 2010 Sep;24(9):1617-30
    4. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Weerkamp F, Dekking E, Ng YY, van der Velden VH, Wai H, Böttcher S, Brüggemann M, van der Sluijs AJ, Koning A, Boeckx N, Van Poecke N, Lucio P, Mendonça A, Sedek L, Szczepański T, Kalina T, Kovac M, Hoogeveen PG, Flores-Montero J, Orfao A, Macintyre E, Lhermitte L, Chen R, Brouwer-De Cock KA, van der Linden A, Noordijk AL, Comans-Bitter WM, Staal FJ, van Dongen JJ; EuroFlow Consortium. Leukemia. 2009 Jun;23(6):1106-17. Epub 2009 Apr 23.
    5. Isolation of human and mouse hematopoietic stem cells. Ng YY, Baert MR, de Haas EF, Pike-Overzet K, Staal FJ. Methods Mol Biol. 2009;506:13-21.
    6. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Leukemia. 2008 Oct;22(10):1849-52
    7. Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. Ng YY, van Kessel B, Lokhorst HM, Baert MR, van den Burg CM, Bloem AC, Staal FJ. J Leukoc Biol. 2004 Feb;75(2):314-23. Epub 2003 Nov 21.
    8. Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells. Ng YY, Bloem AC, van Kessel B, Lokhorst H, Logtenberg T, Staal FJ. Br J Haematol. 2002 Apr;117(1):226-37.
    9. Contaminants from the transplant contribute to intimal hyperplasia associated with microvascular endothelial cell seeding. Arts CH, Hedeman Joosten PP, Blankensteijn JD, Staal FJ, Ng YY, Heijnen-Snyder GJ, Sixma JJ, Verhagen HJ, de Groot PG, Eikelboom BC. Eur J Vasc Endovasc Surg. 2002 Jan;23(1):29-38.
    10. Frape-1 and Frape-3: two different recombinant retroviruses encoding the same human marker gene. Ng YY, Veenhuizen P, Lokhorst H, Staal FJ. Cancer Gene Ther. 2000 Apr;7(4):624-8.
  • #
  • santralistanbul Kampüsü,
    E-3

    Adres: Eski Silahtarağa Elektrik Santralı Kazım Karabekir Cad. No: 2/13 34060 Eyüp İstanbul

Yuk Yin Ng